磷酸氯喹与洛匹那韦利托那韦治疗新型冠状病毒肺炎的疗效和安全性对比研究

Comparison of Efficacy and Safety of Chloroquine Phosphate and Lopinavir/Ritonavir in the Treatment of Patients with COVID-19

目的:比较磷酸氯喹与洛匹那韦利托那韦分别用于新型冠状病毒肺炎(COVID-19)的疗效和安全性,为临床治疗提供用药参考。方法:抽取2020年1-2月惠州市中心人民医院30例确诊COVID-19出院病例(男性19例,女性11例;年龄19~78岁),根据治疗方法的不同,分为研究组(15例,使用磷酸氯喹0.5 g,口服,1日2次)和对照组(15例,使用洛匹那韦利托那韦0.5 g,口服,1日2次),比较两组患者的疗效、不良反应发生情况。结果:研究组患者平均体温恢复正常时间为(2.0±0.3) d,对照组为(3.3±0.6)d,两组的差异有统计学意义(P <0.05);研究组患者平均呼吸道标本病毒核酸转阴性时间为治疗后(3.6±0.4) d,对照组为治疗后(14.0±0.7) d,两组的差异有统计学意义(P <0.05)。研究组患者不良反应发生率为6.7%(1/15),对照组为66.7%(10/15),两组的差异有统计学意义(P <0.05)。结论:磷酸氯喹在改善COVID-19患者的临床症状和加快病毒清除方面优于洛匹那韦利托那韦,且不良反应发生率低。

OBJECTIVE:To compare the efficacy and safety of chloroquine phosphate and lopinavir/ritonavir in the treatment of patients with COVID-19,so as to provide reference for the clinical treatment.METHODS:Thirty confirmed COVID-19 discharged patients(19 males and 11 females,aged from 19 to 78 years)were collected from Huizhou Central People's Hospital from Jan.to Feb.2020.According to different treatment methods,patients were divided into the study group(15 patients,treated with chloroquine 0.5 g,orally,twice a day)and the control group(15 patients,treated with lopinavir/ritonavir 0.5 g,orally,twice a day).The efficacy and adverse drug reactions of two groups were compared.RESULTS:The average body temperature of the patients in the study group returned to normal time was(2.0±0.3)d and that in the control group was(3.3±0.6)d,the difference was statistically significant(P<0.05).The average nucleic acid negative time of respiratory virus specimens in the study group was(3.6±0.4)d after treatment,while that in the control group was(14.0±0.7)d after treatment,with statistically significant difference(P<0.05).The incidence of adverse drug reactions was 6.7%(1/15)in the study group and 66.7%(10/15)in the control group,the difference was statistically significant(P<0.05).CONCLUSIONS:The effect of chloroquine phosphate is superior to lopinavir/ritonavir in improving clinical symptoms and accelerating virus clearance in COVID-19 patients,with the lower incidence of adverse drug reactions.